Studies the effect of BCL6 gene on the sensitivity of Cisplatin in bladder urothelial carcinoma cell lines
碩士 === 國立中山大學 === 生物醫學研究所 === 106 === Cisplatin is one of the most effective anticancer drugs used for treatment of tumors, including bladder, small cell lung and ovarian cancers. During the cisplatin treatment of urothelial cancer, some patients will become to be cisplatin resistance, and then it w...
Main Authors: | Chuan-Wen Hsiao, 蕭傳文 |
---|---|
Other Authors: | Yow-Ling Shiue |
Format: | Others |
Language: | zh-TW |
Published: |
2017
|
Online Access: | http://ndltd.ncl.edu.tw/handle/hgx36c |
Similar Items
-
Studies on the regulatory roles of BCL6 gene on CDC42 and BAX in urinary bladder urothelial carcinoma-derived cell lines
by: Jhih-yu Liu, et al.
Published: (2015) -
Amplification-driven BCL6-enhenced cell cycle progression through FOXO3 signaling pathway in urinary bladder urothelial carcinoma
by: Wen-Ren Wu, et al.
Published: (2019) -
Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment
by: Lena Berning, et al.
Published: (2021-02-01) -
CEBPD-induced SOD1 expression mediates cisplatin resistance in human bladder urothelial carcinoma cell line NTUB1
by: Yan-Liang Lai, et al.
Published: (2009) -
Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines
by: Sung Han Kim, et al.
Published: (2016-01-01)